Metastatic Gastric GIST: How far Can We Go?

Haddadi S, Mammeri MEL, Baba A, Graidia N, Ourdane R, Chahbi MT, Yahia- Messaoud Y, Adjmi S, Belal N, Yaker N and Touati R

Department of General Surgery, Central Hospital of the Army, Dr Mohamed Seghir Nekkache, Algeria The University of Algiers Benyoucef Benkhedda, Algeria Department of Medical Oncology, Central Hospital of the Army, Dr Mohamed Seghir Nekkache, Algeria Department of Medical Imaging, Central Hospital of the Army, Dr Mohamed Seghir Nekkache, Algeria Anatomy and Cytology Pathology Laboratory, Central Hospital of the Army, Dr Mohamed Seghir Nekkache, Algeria

^*Correspondance to: Haddadi S, 

 PDF  Full Text Case Report | Open Access

Abstract:

Gastrointestinal stromal tumors or GISTs have benefited from undeniable progress in both diagnosis and therapy. Thanks to immunohistochemistry and molecular biology, these tumors are increasingly well characterized. And their histoprognostic profile is more accurately assessed. Targeted therapy has changed the therapeutic approach and has allowed surgeons to be increasingly bold in the curative resection of locally advanced and metastatic forms. The aim of this case report is to propose a multidisciplinary vision of the therapeutic management of GISTs, in the light of the experiences acquired within the multidisciplinary committees, and to push the limits of resections even in metastatic forms, which are the only guarantee of a better survival.

Keywords:

GISTs; Diagnostic criteria; Targeted therapy; Multidisciplinary concertation meeting in oncology

Cite the Article:

Haddadi S, Mammeri MEL, Baba A, Graidia N, Ourdane R, Chahbi MT, et al. Metastatic Gastric GIST: How far Can We Go? Clin Case Rep Int. 2023; 7: 1600.